Sirtex Medical Limited is a medical device company, providing a radioactive treatment for inoperable liver cancer called SIR-Spheres microspheres.
Sirtex was established in 1997 in Australia and currently maintains offices and manufacturing facilities in the U.S., Australia, Germany and Singapore. Following an acquisition by China Grand Pharmaceutical and CDH Genetech, Sirtex de-listed from the Australian Securities Exchange (ASX:SRX) on Monday, September 24th 2018.
The company is currently headed by Kevin R. Smith, who was appointed as CEO on October 16, 2019.
Headquarters: Woburn, MA
Products: SIR-Spheres yttrium-90 resin microspheres
Owner: China Grand Pharmaceutical and Healthcare Holdings Ltd./CDH Genetech, Ltd.